Tyra’s dabogratinib advances toward pivotal oncology trials
Dabogratinib, a highly selective oral FGFR3 inhibitor, is advancing toward pivotal trials in IR NMIBC, LG UTUC and ACH, supported by strong Phase 2 efficacy and safety data.
Dabogratinib, a highly selective oral FGFR3 inhibitor, is advancing toward pivotal trials in IR NMIBC, LG UTUC and ACH, supported by strong Phase 2 efficacy and safety data. The drug is aimed at large unmet needs and has market potential exceeding $5 billion, with clear patient and physician…